Judith Greer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9307616/publications.pdf Version: 2024-02-01



IIIDITH COFED

#	Article	IF	CITATIONS
1	Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nature Genetics, 2009, 41, 824-828.	21.4	501
2	An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity, 1995, 3, 397-405.	14.3	412
3	Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis. Journal of Immunology, 1993, 151, 4371-82.	0.8	207
4	A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. Journal of Immunology, 1994, 153, 3326-36.	0.8	150
5	Sexual Dimorphism in Autoimmune Disease. Current Molecular Medicine, 2009, 9, 1058-1079.	1.3	144
6	Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Annals of Neurology, 1998, 44, 980-983.	5.3	137
7	The effect of ageing on human lymphocyte subsets: comparison of males and females. Immunity and Ageing, 2010, 7, 4.	4.2	133
8	Immune dysregulation and selfâ€reactivity in schizophrenia: Do some cases of schizophrenia have an autoimmune basis?. Immunology and Cell Biology, 2005, 83, 9-17.	2.3	127
9	Role of gender in multiple sclerosis: Clinical effects and potential molecular mechanisms. Journal of Neuroimmunology, 2011, 234, 7-18.	2.3	119
10	Identification and characterization of a second encephalitogenic determinant of myelin proteolipid protein (residues 178-191) for SJL mice. Journal of Immunology, 1992, 149, 783-8.	0.8	110
11	Immunogenic and encephalitogenic epitope clusters of myelin proteolipid protein. Journal of Immunology, 1996, 156, 371-9.	0.8	106
12	Immune activation in the peripheral blood of patients with acute ischemic stroke. Journal of Neuroimmunology, 2009, 206, 112-117.	2.3	98
13	Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents. British Journal of Pharmacology, 2003, 138, 819-830.	5.4	94
14	NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis. CNS and Neurological Disorders - Drug Targets, 2008, 7, 536-557.	1.4	86
15	Myelin proteolipid protein—the first 50 years. International Journal of Biochemistry and Cell Biology, 2002, 34, 211-215.	2.8	83
16	Immunology of multiple sclerosis. Current Allergy and Asthma Reports, 2007, 7, 285-292.	5.3	79
17	Genetic analysis of susceptibility to experimental autoimmune encephalomyelitis in a cross between SJL/J and B10.S mice. Journal of Immunology, 1996, 157, 2186-92.	0.8	77
18	Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. Brain, 1997, 120, 1447-1460.	7.6	71

JUDITH GREER

#	Article	IF	CITATIONS
19	Frequency and function of regulatory T cells after ischaemic stroke in humans. Journal of Neuroimmunology, 2012, 243, 89-94.	2.3	70
20	Erythroid differentiation and protoporphyrin IX down-regulate frataxin expression in Friend cells: characterization of frataxin expression compared to molecules involved in iron metabolism and hemoglobinization. Blood, 2002, 99, 3813-3822.	1.4	69
21	A neuropathological analysis of experimental autoimmune encephalomyelitis with predominant brain stem and cerebellar involvement and differences between active and passive induction. Acta Neuropathologica, 2000, 100, 174-182.	7.7	67
22	Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data. Genome Medicine, 2011, 3, 3.	8.2	63
23	Surges of Increased T Cell Reactivity to an Encephalitogenic Region of Myelin Proteolipid Protein Occur More Often in Patients with Multiple Sclerosis Than in Healthy Subjects. Journal of Immunology, 2000, 165, 5322-5331.	0.8	62
24	Blood–brain barrier disruption and lesion localisation in experimental autoimmune encephalomyelitis with predominant cerebellar and brainstem involvement. Journal of Neuroimmunology, 2005, 160, 162-169.	2.3	59
25	Minireview: Autoimmune responses to myelin proteolipid protein. Neurochemical Research, 1994, 19, 915-921.	3.3	58
26	Levels of phosphorylated axonal neurofilament subunit H (pNfH) are increased in acute ischemic stroke. Journal of the Neurological Sciences, 2011, 304, 117-121.	0.6	58
27	Autopathogenic T Helper Cell Type 1 (Th1) and Protective Th2 Clones Differ in Their Recognition of the Autoantigenic Peptide of Myelin Proteolipid Protein. Journal of Experimental Medicine, 1997, 186, 867-876.	8.5	57
28	Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis. Journal of Clinical Neuroscience, 2003, 10, 63-66.	1.5	57
29	Saliva-Derived DNA Performs Well in Large-Scale, High-Density Single-Nucleotide Polymorphism Microarray Studies. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 794-798.	2.5	52
30	The role of epigenetic mechanisms and processes in autoimmune disorders. Biologics: Targets and Therapy, 2012, 6, 307.	3.2	51
31	Female reproductive issues in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 392-402.	3.0	51
32	Circulating brain derived neurotrophic factor (BDNF) and frequency of BDNF positive T cells in peripheral blood in human ischemic stroke: Effect on outcome. Journal of Neuroimmunology, 2015, 286, 42-47.	2.3	47
33	Studies of HLA associations in male and female patients with Guillain–Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Journal of Neuroimmunology, 2006, 180, 172-177.	2.3	42
34	Myelin proteolipid protein: An effective autoantigen and target of autoimmunity in multiple sclerosis. Journal of Autoimmunity, 2008, 31, 281-287.	6.5	40
35	HLAâ \in DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis. Tissue Antigens, 2009, 74, 17-21.	1.0	40
36	Correlation of Blood T Cell and Antibody Reactivity to Myelin Proteins with HLA Type and Lesion Localization in Multiple Sclerosis. Journal of Immunology, 2008, 180, 6402-6410.	0.8	39

JUDITH GREER

#	Article	IF	CITATIONS
37	Comparing genotyping algorithms for Illumina's Infinium whole-genome SNP BeadChips. BMC Bioinformatics, 2011, 12, 68.	2.6	38
38	A parasite-derived 68-mer peptide ameliorates autoimmune disease in murine models of Type 1 diabetes and multiple sclerosis. Scientific Reports, 2016, 6, 37789.	3.3	34
39	Early pregnancy factor suppresses experimental autoimmune encephalomyelitis induced in Lewis rats with myelin basic protein and in SJL/J mice with myelin proteolipid protein peptide 139-151. Journal of the Neurological Sciences, 2000, 182, 5-15.	0.6	33
40	Chemokines and Chemokine Receptors: Potential Therapeutic Targets in Multiple Sclerosis. Inflammation and Allergy: Drug Targets, 2004, 3, 279-290.	3.1	32
41	Effect of gender on T-cell proliferative responses to myelin proteolipid protein antigens in patients with multiple sclerosis and controls. Journal of Autoimmunity, 2004, 22, 345-352.	6.5	31
42	Closing the case of <i>APOE</i> in multiple sclerosis: no association with disease risk in over 29â€000 subjects: Figure 1. Journal of Medical Genetics, 2012, 49, 558-562.	3.2	31
43	Thiopalmitoylation of Myelin Proteolipid Protein Epitopes Enhances Immunogenicity and Encephalitogenicity. Journal of Immunology, 2001, 166, 6907-6913.	0.8	29
44	The presence of glutamic acid at positions 71 or 74 in pocket 4 of the HLA-DRÂ1 chain is associated with the clinical course of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 656-662.	1.9	28
45	Increased circulating T cell reactivity to GM1 ganglioside in patients with Guillain–Barré syndrome. Journal of Clinical Neuroscience, 2005, 12, 409-415.	1.5	27
46	Route of Uptake of Palmitoylated Encephalitogenic Peptides of Myelin Proteolipid Protein by Antigen-Presenting Cells: Importance of the Type of Bond between Lipid Chain and Peptide and Relevance to Autoimmunity. Journal of Immunology, 2008, 180, 1398-1404.	0.8	25
47	Autoimmune T-Cell Reactivity to Myelin Proteolipids and Glycolipids in Multiple Sclerosis. Multiple Sclerosis International, 2013, 2013, 1-16.	0.8	24
48	PLP1 Mutations in Patients with Multiple Sclerosis: Identification of a New Mutation and Potential Pathogenicity of the Mutations. Journal of Clinical Medicine, 2018, 7, 342.	2.4	23
49	Prolonged elevation of cytokine levels after human acute ischaemic stroke with evidence of individual variability. Journal of Neuroimmunology, 2012, 246, 78-84.	2.3	22
50	Elevated levels of autoantibodies targeting the M1 muscarinic acetylcholine receptor and neurofilament medium in sera from subgroups of patients with schizophrenia. Journal of Neuroimmunology, 2014, 269, 68-75.	2.3	19
51	Interleukin-6 Gene Promoter-572 C Allele May Play a Role in Rate of Disease Progression in Multiple Sclerosis. International Journal of Molecular Sciences, 2012, 13, 13667-13679.	4.1	17
52	Novel Therapeutics for Multiple Sclerosis Designed by Parasitic Worms. International Journal of Molecular Sciences, 2017, 18, 2141.	4.1	17
53	CTLA-4 single-nucleotide polymorphisms in a Caucasian population with schizophrenia. Brain, Behavior, and Immunity, 2009, 23, 347-350.	4.1	16
54	Orientation of myelin proteolipid protein in the oligodendrocyte cell membrane. Neurochemical Research, 1996, 21, 431-440.	3.3	15

Judith Greer

#	Article	IF	CITATIONS
55	Encephalitogenicity of murine, but not bovine, DM20 in SJL mice is due to a single amino acid difference in the immunodominant encephalitogenic epitope. Neurochemical Research, 1997, 22, 541-547.	3.3	15
56	Characterization of a new rat model for chronic inflammatory demyelinating polyneuropathies. Journal of Neuroimmunology, 2015, 278, 1-10.	2.3	15
57	Correlation Between Anti-Myelin Proteolipid Protein (PLP) Antibodies and Disease Severity in Multiple Sclerosis Patients With PLP Response-Permissive HLA Types. Frontiers in Immunology, 2020, 11, 1891.	4.8	14
58	Immunolocalization of proteolipid protein peptide 103-116 in myelin. Journal of Neuroscience Research, 1994, 37, 36-43.	2.9	13
59	Increased constitutive activation of NF-κB p65 (RelA) in peripheral blood cells of patients with progressive multiple sclerosis. Journal of Neuroimmunology, 2018, 320, 111-116.	2.3	13
60	An investigation of the C77G and C772T variations within the human protein tyrosine phosphatase receptor type C gene for association with multiple sclerosis in an Australian population. Brain Research, 2009, 1255, 148-152.	2.2	12
61	Gene Expression in the Spinal Cord in Female Lewis Rats with Experimental Autoimmune Encephalomyelitis Induced with Myelin Basic Protein. PLoS ONE, 2012, 7, e48555.	2.5	12
62	The Role of HLA in MS Susceptibility and Phenotype. Current Topics in Behavioral Neurosciences, 2014, 26, 1-27.	1.7	11
63	Prominent brainstem and cerebellar involvement in multiple sclerosis with psoriasis. Multiple Sclerosis Journal, 2009, 15, 763-766.	3.0	10
64	Correlation of Adrenomedullin gene expression in peripheral blood leukocytes with severity of ischemic stroke. International Journal of Neuroscience, 2014, 124, 271-280.	1.6	10
65	Quantitative Proteome Profiling of CNS-Infiltrating Autoreactive CD4 ⁺ Cells Reveals Selective Changes during Experimental Autoimmune Encephalomyelitis. Journal of Proteome Research, 2014, 13, 3655-3670.	3.7	10
66	Solid-phase synthesis of a biotin-labelled thiopalmitoylated myelin proteolipid protein epitope and application in the study of uptake of antigen by macrophages. International Journal of Peptide Research and Therapeutics, 2003, 10, 581-588.	0.1	8
67	Taming the TCR: Antigen-Specific Immunotherapeutic Agents for Autoimmune Diseases. International Reviews of Immunology, 2015, 34, 460-485.	3.3	8
68	Interleukin 6 promoter 174 G/C polymorphisms in acute ischemic stroke: G allele is protective but not associated with IL-6 levels or stroke outcome. Journal of Neuroimmunology, 2016, 293, 22-27.	2.3	8
69	Reactivity to Novel Autoantigens in Patients with Coexisting Central Nervous System Demyelinating Disease and Autoimmune Thyroid Disease. Frontiers in Immunology, 2017, 8, 514.	4.8	8
70	Autoantibodies and their potential roles in diseases of the nervous system. Clinical and Experimental Neuroimmunology, 2015, 6, 370-386.	1.0	7
71	Is there a role for antibodies targeting muscarinic acetylcholine receptors in the pathogenesis of schizophrenia?. Australian and New Zealand Journal of Psychiatry, 2019, 53, 1059-1069.	2.3	7
72	Comparison of T suppressor factors from tumour-bearing mice and mice immunized with a monoclonal anti-idiotypic antibody. Cancer Immunology, Immunotherapy, 1990, 31, 151-156.	4.2	5

JUDITH GREER

#	Article	IF	CITATIONS
73	Thiopalmitoylation of Altered Peptide Ligands Enhances Their Protective Effects in an Animal Model of Multiple Sclerosis. Journal of Immunology, 2014, 192, 2244-2251.	0.8	5
74	Chapter 29 Expression of myelin proteolipid protein in oligodendrocytes and transfected cells. Progress in Brain Research, 1995, 105, 295-303.	1.4	4
75	Investigation of the [â^'/A]8and C1236T genetic variations within the human toll-like receptor 3 gene for association with multiple sclerosis. Neurological Research, 2010, 32, 438-441.	1.3	4
76	Solid-phase synthesis of a biotin-labelled thiopalmitoylated myelin proteolipid protein epitope and application in the study of uptake of antigen by macrophages. International Journal of Peptide Research and Therapeutics, 2003, 10, 581-587.	1.9	3
77	Sexual Dimorphism in the Immune System. , 2014, , 319-328.		3
78	Autoâ€antiâ€idiotypic antibodies in mice hyperimmunized with a chemically induced bladder carcinoma. Immunology and Cell Biology, 1988, 66, 167-173.	2.3	2
79	Effects of anti-idiotype vaccine on tumour growth and on production of soluble factors modulating cell-mediated immunity in vitro. Cancer Immunology, Immunotherapy, 1991, 33, 171-176.	4.2	2
80	Increased expression of the hypoxiaâ€related genes in peripheral blood leukocytes of human subjects with acute ischemic stroke. Clinical and Experimental Neuroimmunology, 2014, 5, 216-226.	1.0	2
81	Sexual Dimorphism in the Immune System. , 2020, , 419-428.		2
82	Reduced IκB-α Protein Levels in Peripheral Blood Cells of Patients with Multiple Sclerosis—A Possible Cause of Constitutive NF-κB Activation. Journal of Clinical Medicine, 2020, 9, 2534.	2.4	2
83	HLA and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 0, , 1-9.	1.7	2
84	Predicting the effects of potentially therapeutic modified peptides on polyclonal T cell populations in a mouse model of multiple sclerosis. Journal of Neuroimmunology, 2017, 307, 18-26.	2.3	1
85	Distinctive molecular markers and biological activities in two tumourâ€specific murine T suppressor factors. Immunology and Cell Biology, 1991, 69, 135-143.	2.3	0
86	Study of leukemia inhibitory factor polymorphism within an Australian multiple sclerosis population. Journal of the Neurological Sciences, 2009, 280, 62-64.	0.6	0
87	Characterization of genetic variants in the NFKBIA promoter region in multiple sclerosis. Journal of Neuroimmunology, 2014, 275, 53-54.	2.3	0
88	PLP1 mutations in patients with multiple sclerosis: Identification of a new mutation and analysis of in vitro effects of PLP1 mutations. Journal of Neuroimmunology, 2014, 275, 100.	2.3	0